BIO vs CRL
As of Sep 20, 2026, Bio-Rad Laboratories (BIO) scores 7.4/10 and Charles River Laboratories International (CRL) 6.2/10 on AlphaStocks' five-model composite, so BIO scores higher. CRL trades 51% above its model fair value.
BIO
BIO-RAD LABORATORIES, INC.
7.4
Consider Buy
$375.68
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
6.2
Consider Buy
$277.64
BIO vs CRL: Which is the Better Investment?
BIO-RAD LABORATORIES, INC. (BIO) scores 7.4/10 while CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) scores 6.2/10 on AlphaStocks' composite model. BIO-RAD LABORATORIES, INC. has the higher composite rating of Consider Buy.
This comparison is algorithmically generated and is not financial advice.
| Metric | BIO | CRL |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 7.4/10▲ | 6.2/10 |
| Rating | Consider Buy▲ | Consider Buy |
| Price | $375.68 | $277.64 |
| P/E Ratio | 13.5 | — |
| ROE | 9.7%▲ | -4.4% |
| Market Cap | $10B | $14B |
| Fair Value | — | $183.88 |
| Dividend Yield | — | — |
| Sector Rank | #7 of 168▲ | #45 of 168 |
| Model Verdicts | ||
| Piotroski | Attractive | Attractive |
| Buffett | Neutral | Neutral |
| Graham | Attractive▲ | Caution |
| Lynch | Attractive | Attractive |
| Greenblatt | Strong▲ | Neutral |
Related comparisons
BIO vs CRL: Which Stock Scores Higher?
BIO-RAD LABORATORIES, INC. (BIO) and CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) are both in the Health Care sector. BIO currently leads with a composite score of 7.4/10 (Consider Buy) compared to CRL's 6.2/10 (Consider Buy).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer